查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1763179

全球性病检测市场

STD Testing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2030年全球性病检测市场规模将达1,448亿美元

全球性传染病检测市场规模预计在2024年为1,070亿美元，预计到2030年将达到1,448亿美元，在2024-2030年的分析期内，复合年增长率为5.2%。披衣菌感染是本报告分析的细分市场之一，预计其复合年增长率为5.0%，到分析期结束时规模将达到406亿美元。单纯疱疹病毒细分市场在分析期间的复合年增长率估计为6.0%。

美国市场规模估计为 284 亿美元，中国市场预计复合年增长率为 8.2%

预计到2024年，美国性病检测市场规模将达284亿美元。作为世界第二大经济体，中国市场规模预计到2030年将达到315亿美元，在2024-2030年的分析期间内，复合年增长率为8.2%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为2.8%和4.2%。在欧洲，预计德国市场的复合年增长率为3.6%。

全球性病检测市场－主要趋势与驱动因素摘要

为什么性病检测变得如此紧迫并且受到全世界如此关注？

全球性行为感染传染病 (STD) 发生率不断上升，导致对 STD 检测服务的需求大幅增加。性行为改变、意识缺乏以及安全操作教育不足等因素导致 STD 病例急剧增加。为此，医疗保健组织和政府正在提倡早期诊断和定期检测，以遏制感染传播并改善患者预后。公共卫生宣传活动的扩大和医疗服务可近性的改善（尤其是在发展中地区）也促使人们更加重视 STD 检测。由于爱滋病毒、披衣菌感染、淋病和梅毒等疾病仍然是主要的公共卫生问题，可访问、可靠和快速的检测解决方案的重要性不断增加，凸显了全球对全面检测计划的迫切需求。

科技进步如何影响性病检测格局？

旨在提高诊断速度、准确性和可及性的技术进步正在重塑性病检测市场。照护现场(POC) 设备越来越受欢迎，无需实验室处理即可快速获得结果，这对于早期疗育和治疗至关重要。聚合酵素链锁反应(PCR) 检测等分子诊断方法正在提高性病检测的准确性，可以从单一样本中识别出多种病原体。可在家中自行使用的自测检测套组也越来越受欢迎，因为它们为个人管理性健康提供了一种方便、谨慎的方式。行动医疗(行动医疗) 平台的整合将使用者与医疗专业人员联繫起来，进行远距咨询和结果解释，这进一步提高了性病检测服务的覆盖范围和效率，尤其是在偏远和服务不足的地区。

哪些市场趋势影响了对性病检测服务的需求？

性健康意识的增强和性传染病（尤其是青少年性传染病）的流行正在显着影响对性传染病检测服务的需求。教育宣传活动和公共卫生倡议，特别是针对青少年、LGBTQ+ 群体和性工作者等高风险群体，强调了定期检测和早期诊断的重要性。预防性医疗和个人化医疗的转变也发挥了作用，医疗保健提供者提倡主动筛检和定期检查，以减轻感染疾病的传播。此外，远端医疗服务的扩展提供了便捷的性传染病检测和咨询服务，使检测更容易获得和更具吸引力，特别是在 COVID-19 大流行之后远距医疗解决方案的采用加速的情况下。这些趋势表明，作为综合医疗保健管理的一部分，对常规性传染病检测的接受度和需求增加。

哪些因素推动了性病检测市场的成长？

性病检测市场的成长受到多种因素的推动，包括性传染病盛行率上升、诊断工具的技术进步以及对预防性医疗保健的日益重视。就地检验技术的扩展和家用检测套组的普及使检测更加便捷，特别是对于那些注重隐私和便利的个人而言。分子诊断的整合提高了检测结果的准确性和速度，吸引了寻求有效方法控制和预防感染疾病传播的医疗保健提供者。公共卫生计画和教育宣传活动也在扩大检测管道，特别是在医疗保健基础设施正在改善的开发中地区。此外，远端医疗服务的广泛采用使偏远地区也可以进行咨询和检测，进一步推动了市场成长。这些综合因素推动了性病检测市场的扩张，使其成为现代医疗保健的重要组成部分。

部分

疾病类型（披衣菌感染、单纯疱疹病毒、淋病、人类乳突病毒 (HPV)、梅毒、其他疾病类型）、地点（实验室、照护现场(POC)）

受访公司范例

  • Alere, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.

人工智慧集成

全球产业分析师正在利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global 特定产业SLM 的典型规范，而是建立了一个从全球专家收集的内容库，其中包括视讯录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况（成品和原始OEM）预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP16316

Global STD Testing Market to Reach US$144.8 Billion by 2030

The global market for STD Testing estimated at US$107.0 Billion in the year 2024, is expected to reach US$144.8 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Chlamydia, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$40.6 Billion by the end of the analysis period. Growth in the Herpes Simplex Virus segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$28.4 Billion While China is Forecast to Grow at 8.2% CAGR

The STD Testing market in the U.S. is estimated at US$28.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$31.5 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 4.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global STD Testing Market - Key Trends & Drivers Summarized

Why Is STD Testing Gaining Urgency and Attention Worldwide?

The rising prevalence of sexually transmitted diseases (STDs) across the globe has led to a significant increase in demand for STD testing services. Factors such as changing sexual behavior, lack of awareness, and inadequate education on safe practices have contributed to the surge in STD cases. In response, healthcare organizations and governments are promoting early diagnosis and routine testing to curb the spread of infections and improve patient outcomes. The expansion of public health campaigns and increased access to healthcare services, particularly in developing regions, are also contributing to the emphasis on STD testing. With diseases like HIV, chlamydia, gonorrhea, and syphilis being major public health concerns, the importance of accessible, reliable, and rapid testing solutions continues to grow, underscoring the urgent need for comprehensive testing programs worldwide.

How Are Technological Advancements Influencing the STD Testing Landscape?

The STD testing market is being reshaped by technological advancements aimed at improving diagnostic speed, accuracy, and accessibility. Point-of-care (POC) testing devices are becoming increasingly popular, offering rapid results without the need for laboratory processing, which is essential for early intervention and treatment. Molecular diagnostics, such as polymerase chain reaction (PCR) tests, are enhancing the precision of STD detection, allowing for the identification of multiple pathogens from a single sample. Self-testing kits, which can be used privately at home, are also gaining traction as they provide a convenient and discreet way for individuals to manage their sexual health. The integration of mobile health (mHealth) platforms that connect users with healthcare professionals for remote consultations and result interpretation is further enhancing the reach and efficiency of STD testing services, especially in remote or underserved areas.

What Are the Market Trends Influencing the Demand for STD Testing Services?

The increasing awareness of sexual health and the rising prevalence of STDs, particularly among the younger population, are significantly influencing the demand for STD testing services. Educational campaigns and public health initiatives, particularly those targeting at-risk groups like young adults, LGBTQ+ communities, and sex workers, are emphasizing the importance of regular testing and early diagnosis. The shift towards preventive healthcare and personalized medicine is also playing a role, as healthcare providers advocate for proactive screening and routine check-ups to mitigate the spread of infections. Additionally, the expansion of telemedicine services, which offer convenient access to STD testing and consultations, is making testing more accessible and appealing, particularly in the wake of the COVID-19 pandemic, which accelerated the adoption of remote healthcare solutions. These trends indicate a growing acceptance and demand for routine STD testing as part of comprehensive healthcare management.

What Factors Are Driving the Growth of the STD Testing Market?

The growth in the STD testing market is driven by several factors, including the rising prevalence of STDs, technological advancements in diagnostic tools, and the increasing emphasis on preventive healthcare. The expansion of point-of-care testing technologies and the availability of at-home testing kits are making testing more accessible, particularly for individuals who prefer privacy and convenience. The integration of molecular diagnostics, which enhances the accuracy and speed of test results, is attracting healthcare providers looking for efficient ways to manage and prevent the spread of infections. Public health initiatives and educational campaigns are also expanding testing access, particularly in developing regions where healthcare infrastructure is improving. Additionally, the widespread adoption of telemedicine services is facilitating remote consultations and access to testing, further supporting market growth. These combined factors are propelling the expansion of the STD testing market, making it a critical component of modern healthcare.

SCOPE OF STUDY:

The report analyzes the STD Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis, Other Disease Types); Location (Laboratory, Point-of-Care (POC))

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • Alere, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Tariff Impact on Global Supply Chain Patterns
    • STD Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Sexually Transmitted Diseases (STDs) Worldwide
    • Increasing Demand for Rapid and Point-of-Care Testing Solutions
    • Growth in Awareness Campaigns Promoting Routine STD Testing
    • Expansion of At-Home Testing Kits for Privacy and Convenience
    • Surge in Telemedicine Services Facilitating Remote STD Testing
    • Technological Advancements in Multiplex and PCR-Based Tests
    • Growing Focus on Early Detection and Preventive Healthcare
    • Rising Use of Mobile Health (mHealth) Apps for Test Scheduling and Results
    • Development of Combination Test Kits Covering Multiple STDs
    • Increasing Availability of Affordable STD Testing Solutions in Emerging Markets
    • Growth in Use of Self-Collection Kits for Enhanced Patient Comfort
    • Rising Collaboration Between Public Health Organizations and Testing Providers
    • Expansion of Laboratory Infrastructure Supporting High-Volume Testing
    • Surge in Demand for Digital Platforms Offering Confidential STD Testing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World STD Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for STD Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for STD Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Chlamydia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Herpes Simplex Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Gonorrhea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Human Papillomavirus (HPV) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Human Papillomavirus (HPV) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Syphilis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Laboratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Laboratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Laboratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Point-of-Care (POC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Point-of-Care (POC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Point-of-Care (POC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • JAPAN
    • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • CHINA
    • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • EUROPE
    • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for STD Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for STD Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • FRANCE
    • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • GERMANY
    • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for STD Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • INDIA
    • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for STD Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for STD Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for STD Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for STD Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030
  • AFRICA
    • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2015, 2025 & 2030

IV. COMPETITION